

Table of contents

**ABSTRACT ..... I**

**ZUSAMMENFASSUNG ..... III**

**LIST OF FIGURES .....VIII**

**LIST OF TABLES..... X**

**ABBREVIATIONS..... XI**

**A. INTRODUCTION.....1**

1. PLURIPOTENT STEM CELLS AND EPIGENETIC REGULATION OF PLURIPOTENCY.....1

1.1. *Characteristics of pluripotent stem cells* ..... 1

1.2. *The core pluripotency network and intrinsic markers of pluripotency* .....3

1.3. *History and features of epigenetics* .....5

1.4. *ESCs display a unique epigenetic landscape* .....7

1.5. *DNA methylation and mESCs* .....9

1.6. *Epigenetic events during preimplantation development of the mouse embryo* ..... 10

2. PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA-LIKE 7 (PRAMEL7) .....13

2.1. *PRAME, the founding member of a big gene family* ..... 13

2.2. *Pramel7 and other PRAME-like proteins* ..... 14

3. UBIQUITIN-LIKE, CONTAINING PHD AND RING FINGER DOMAINS, 1 (UHRF1): AN IMPORTANT REGULATOR OF EPIGENETIC PATTERNING .....16

3.1. *Nomenclature and protein architecture* ..... 16

3.2. *UHRF1 is involved in the maintenance of DNA methylation* ..... 17

3.2.1. *UHRF1 is essential for the maintenance of global DNA methylation*..... 17

3.2.2. *The SRA domain mediates the recognition of hemimethylated DNA*..... 18

3.2.3. *Subsequent studies characterizing the epigenetic function of UHRF1* ..... 19

3.3. *The C-terminal RING domain and its function as an E3 ubiquitin ligase* ..... 19

3.4. *PHD- and Tandem-Tudor domains are recognizing the N-terminal tail of H3* .....22

3.4.1. *PHD fingers can read the histone code* ..... 22

3.4.2. *The Tandem-Tudor domain recognizes modifications of the H3-tail* ..... 22

3.4.3. *UHRF1 in targeting the N-terminal H3-tail* ..... 23

**AIM OF THE WORK .....25**

**B. RESULTS .....26**

1. DISCOVERING INTERACTION PARTNERS OF PRAMEL7 .....26

1.1. *Screening for potent interaction partners* .....26

1.2. *Generation of a polyclonal antibody specifically recognizing Pramel7* .....27

1.3. *Pramel7 is interacting with UHRF1 in HEK293T cells and mESCs* .....28

1.4. *Mass spectrometry reveals additional binding partners of Pramel7-UHRF1* .....29

1.5. *Mutated forms of Pramel7 show impaired binding to UHRF1* .....34

1.6. *Mutant forms of UHRF1 interact with Pramel7 at different strength* .....36

2. MOLECULAR EFFECTS CAUSED BY THE INTERACTION BETWEEN PRAMEL7 AND UHRF1 .....	39
2.1. <i>Pramel7 as a potential recognition subunit of an E3-ligase complex</i> .....	39
2.2. <i>HEK293T and mESCs overexpressing Pramel7 display drastically reduced levels of UHRF1</i> .....	40
2.3. <i>When ectopic expression of Pramel7 is lost, UHRF1 amounts are restored to wt levels</i> .....	42
2.4. <i>Is Pramel7 inducing the degradation of UHRF1 through the 26S-proteasome?</i> .....	44
2.5. <i>Forms of Pramel7 mutated in the LRR-region cannot induce the degradation of UHRF1</i> .....	45
2.6. <i>Pramel7 is unable to degrade different mutant forms of UHRF1</i> .....	46
2.7. <i>Reduction of UHRF1 results in decreased levels of DNA methylation</i> .....	46
2.7.1. <i>Digestion of genomic DNA from mESCs with methylation-sensitive restriction enzymes</i> .....	46
2.7.2. <i>Confocal microscopy reveals reduced signals for 5mC in mESCs overexpressing Pramel7</i> .....	48
2.7.3. <i>Pramel7-overexpressing mESCs exhibit elevated expression levels of the trophectodermal marker Elf5</i> .....	49
2.8. <i>Chromatin of Pramel7-overexpressing mESCs is enriched in activating histone marks</i> .....	50
2.9. <i>Overexpression of Pramel7 is not altering cell cycle profiles of HEK293T and mESCs</i> .....	51
2.10. <i>Localization of Pramel7 in the cell</i> .....	52
2.11. <i>Compared to Pramel7, PRAME exhibits a similar expression pattern in HEK293T cells</i> .....	53
2.12. <i>PRAME and Pramel6 are not able to reduce UHRF1 levels after ectopic expression</i> .....	54
3. A BIOLOGICAL CONSEQUENCE OF PRAMEL7 EXPRESSION IN MESCOs .....	55
3.1. <i>mESCs overexpressing Pramel7 show impaired terminal differentiation</i> .....	55
3.1.1. <i>After 14 days of differentiation, Pramel7-overexpressing mESCs exhibit a drastically elevated expression of pluripotency-related genes</i> .....	55
3.1.2. <i>Upon addition of LIF, differentiated mESCs overexpressing Pramel7 rapidly regain features associated with pluripotency</i> .....	56
3.1.3. <i>Expansion of reconverted E14-clones requires a longer cultivation period than of re-converted mESCs overexpressing Pramel7</i> .....	58
3.1.4. <i>Reconverted Pramel7-clones still exhibit downregulated UHRF1 and ectopic expression of Pramel7</i> .....	59
3.1.5. <i>Reconverted E14-clones fail to reactivate the expression of the pluripotency-related genes Rex1 and Pramel7</i> .....	59
3.2. <i>Pramel7-overexpressing mESCs are able to differentiate into cells positive for smooth muscle actin (SMA)</i> .....	60
C. DISCUSSION .....	62
1. UHRF1, A NEW INTERACTION PARTNER OF PRAMEL7 .....	62
2. ADDITIONAL INTERACTION PARTNERS .....	65
3. PRAMEL7 AS A SUBSTRATE-RECOGNITION COMPONENT OF AN E3-LIGASE COMPLEX .....	66
4. OVEREXPRESSION OF PRAMEL7 SEVERELY REDUCES GLOBAL DNA METHYLATION IN MESCOs .....	69
5. FUTURE PERSPECTIVES AND CONCLUDING REMARKS .....	71
D. MATERIALS .....	74
1. CELL CULTURE MEDIA AND SUPPLEMENTS .....	74
2. PLASMIDS .....	76
2.1. <i>Pramel7 expression constructs</i> .....	76

2.2. <i>UHRF1</i> expression constructs .....	78
2.3. Other expression constructs.....	79
3. CELL LINES.....	80
4. BUFFERS AND SOLUTIONS.....	81
<b>E. METHODS .....</b>	<b>83</b>
1. CLONING .....	83
2. WESTERN BLOTTING .....	83
3. RNA EXTRACTION, REVERSE TRANSCRIPTION AND QUANTITATIVE REAL-TIME PCR (RTQ-PCR) .....	84
4. IMMUNOFLUORESCENT DETECTION (WIDE FIELD/CONFOCAL) AND ALKALINE PHOSPHATASE STAINING .....	86
5. YEAST-TWO HYBRID ASSAY .....	87
6. DERIVATION AND TESTING OF AN ANTIBODY RECOGNIZING PRAMEL7 .....	87
7. CO-IMMUNOPRECIPITATION, TCA PRECIPITATION AND SILVER STAINING (MAMMALIAN CELLS) .....	87
7.1. <i>Analysis by Western blotting</i> .....	87
7.2. <i>TCA precipitation for proteomic analysis</i> .....	88
7.3. <i>Silver staining</i> .....	88
8. CELL CULTURE EXPERIMENTS.....	89
8.1. <i>CaCl<sub>2</sub>-transfection of plasmid DNA in HEK293T</i> .....	89
8.2. <i>Transfection of plasmid DNA in HEK293T cells using transfection reagent</i> .....	89
8.3. <i>Separation of mESCs from feeders, electroporation of plasmid DNA, selection and expansion of ESCs</i> .....	89
8.4. <i>Time course experiment UHRF1 degradation</i> .....	90
8.5. <i>Inhibition of UHRF1-degradation by MG132</i> .....	90
8.6. <i>MG132 functionality test</i> .....	90
8.7. <i>Differentiation and reversion of wildtype E14 and CAG_FLAGHA-Pramel7-overexpressing mESCs</i> .....	91
8.8. <i>Smooth muscle differentiation</i> .....	91
9. ISOLATION OF GENOMIC DNA AND METHYLATION-SENSITIVE RESTRICTION DIGESTION .....	91
9.1. <i>Isolation of genomic DNA</i> .....	91
9.2. <i>Restriction digestion for methylation assay</i> .....	92
10. PI-STAINING OF DNA FOR FLOW CYTOMETRY .....	92
<b>F. BIBLIOGRAPHY.....</b>	<b>93</b>
<b>CURRICULUM VITAE.....</b>	<b>108</b>